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Introduction {#sec1}
============

The lymphatic vascular system is responsible for tissue fluid homeostasis, lipid absorption, and mediation of immune responses. It initiates as a network of blind-ended capillaries throughout most organs of the body. These capillaries have discontinuous tight junctions in order to take up free fluid and solutes from the interstitium or lipids from the intestinal tract. Antigen-presenting cells, as well as antigen itself, enter the lymphatic system at the level of the capillaries before being conducted into collecting lymphatic vessels (LVs). Concurrent with an increasing diameter, collecting LVs are covered by a thin layer of smooth muscle cells that are required for the intrinsic contractility of lymphatic collectors ([@bib16], [@bib48]). Together with intraluminal valves, their active contractions ensure unidirectional lymph flow against an increasing pressure gradient. Collecting LVs conduct lymph through one or more lymph nodes until it ultimately reaches the bloodstream at the subclavian veins.

The mechanisms regulating collecting LV contractility are not entirely understood. Generally, there are both extrinsic and intrinsic factors that influence lymph flow. Extrinsic factors include the passive movement of lymph by contractions of striated muscles (e.g., during walking), as well as by nearby arteries, which through vasomotion can conduct their pulsation to LVs ([@bib16], [@bib48]). With regard to intrinsic mechanisms, mechanical parameters such as shear stress and intraluminal pressure gradients within the LVs exert important influences on smooth muscle cell behavior (reviewed in [@bib37]). Vasoregulatory factors, including nitric oxide (NO), also have a strong influence on the contractility. NO is an effective vasodilator and has negative inotropic effects on LVs ([@bib36]). The release of NO is induced by high shear stress within the vessel ([@bib22], [@bib23]) or by a variety of signaling molecules such as vascular endothelial growth factor A (VEGF-A) ([@bib24]). Surprisingly, the potential regulation of LV contractility by the autonomic nervous system has not received much attention thus far.

Nerves in close proximity to LVs have been described in humans ([@bib10], [@bib11]) and large animals, including cows and dogs ([@bib31], [@bib45]), and *ex vivo* studies have reported responses of the contraction pattern of isolated LVs to several neurotransmitters ([@bib27], [@bib25], [@bib28]). However, the results of these *ex vivo* studies are somewhat contradictory. While previous studies consistently found activation of lymphatic contractility by the α-adrenergic nervous system, some attributed these effects solely to the activation of α~1~ receptors ([@bib3]), whereas others reported that only α~2~ receptors, but not α~1~ receptors, are needed ([@bib18]). Similarly, conflicting results have been reported regarding the role of the muscarinic nervous system, since its agonist acetylcholine (ACh) induced LV relaxation ([@bib15], [@bib18], [@bib29]) as well as contraction ([@bib30]). Recently, *ex vivo* studies using human tissue found a strong induction of LV contracting activity by the adrenergic agonist norepinephrine (NE) and an inhibitory effect of the muscarinic antagonist atropine ([@bib43], [@bib44]). Overall, most of the current knowledge about the interaction between the autonomic nervous system and LV contractility stems from *ex vivo* studies, while *in vivo* studies are still lacking ([@bib4], [@bib32]). Importantly, virtually nothing is known about potentially different responses of LVs to neurotransmitters in pathological conditions such as chronic inflammation and cancer, where LVs play major pathogenetic roles ([@bib8], [@bib40]).

In this study, we investigated in detail the role of the autonomic nervous system in the regulation of LV function under physiological and pathological conditions. To this end, we first studied the presence of different subtypes of nerves on murine LVs and analyzed the expression profile of neurotransmitter receptors on lymphatic endothelial cells (LECs) *in vitro* and *in situ*. These studies revealed organ-specific expression patterns that might explain previously reported diverging effects of neurotransmitters in different organs. We then applied quantitative *in vivo* near-infrared imaging techniques to directly investigate the effects of a broad spectrum of agonists and antagonists of the autonomic nervous system on the contraction frequency and amplitude of collecting LVs under physiological conditions. These investigations were accompanied by live Ca^2+^ imaging studies *in vitro* and *in vivo*. Finally, we investigated the effects of selected neurotransmitters on tumor-draining LVs. Our results reveal that under physiological conditions, contractions of collecting LVs are activated via α-adrenergic and muscarinic receptors, while they are inhibited via activation of β~2~-adrenergic receptors. Importantly, we found that tumor-draining LVs exhibited more active contractility and that this contraction activity can be inhibited by distinct agonists and antagonists of the autonomic nervous system.

Results {#sec2}
=======

Neurotransmitter Receptors Are Expressed on LVs in an Organ-Specific Manner {#sec2.1}
---------------------------------------------------------------------------

We first investigated the mRNA expression levels of all known adrenergic and muscarinic neurotransmitter receptors in five different primary human dermal LEC lines. LECs specifically expressed β~1~- and β~2~-adrenergic receptors ([Figure 1](#fig1){ref-type="fig"}A shows two cell lines, and [Figure S1](#mmc1){ref-type="supplementary-material"}A the additional three lines). These findings were confirmed at the protein level by western blot ([Figure 1](#fig1){ref-type="fig"}A), with human bronchial smooth muscle cells (hBSMCs) serving as a positive control and the tumor cell line MeWo as a negative control. In a next step, we investigated the neurotransmitter receptors expressed in mouse tissue. Whole-mount staining of the flank collecting LVs and lacteal villi in the small intestine was performed. Adrenergic α~1~ receptors were present on CD31^+^ LECs as well as on the αSMA^+^ smooth muscle cells of the flank collector ([Figure 1](#fig1){ref-type="fig"}B). In contrast to the collecting LVs, neither the intestinal LYVE-1^+^ lacteals nor their associated smooth muscle cells (αSMA^+^) demonstrated expression of α~1~ receptors ([Figure 1](#fig1){ref-type="fig"}C). Interestingly, the mesenteric collecting LVs lacked expression of α~1~ receptors ([Figure S1](#mmc1){ref-type="supplementary-material"}F). Whole-mount staining revealed no detectable expression of β~1~ receptors on either type of LVs ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C), whereas the β~2~ receptors were expressed on LECs of all vessel types, lacteals, the flank, and mesenteric collectors ([Figures 1](#fig1){ref-type="fig"}D, 1E, and [S1](#mmc1){ref-type="supplementary-material"}G). β~2~-Receptor expression was also detected on smooth muscle cells of the flank and mesenteric collecting LVs, but not on the smooth muscle cells surrounding the lacteal.Figure 1Neurotransmitter Receptors Are Expressed on LVs in an Organ-Specific Manner(A) qPCR-based detection of adrenergic β~1~ and β~2~ receptor (*ADRB1* and *ADRB2*) mRNA in two primary human LEC lines (shown as blue and blue-striped columns). Expression was confirmed at the protein level using western blots with human bronchial smooth muscle cells (hBSMCs) as a positive control and the tumor cell line MeWo as a negative control.(B, D, and F) Whole-mount staining of flank collector showing α~1~ (B), β~2~ (D), and M2 (F) receptors expressed on CD31^+^ LECs and αSMA^+^ smooth muscle cells. Asterisks indicate β~2~-positive CD31^+^ blood vessels, and open arrowheads indicate β~2~-positive adipocytes.(C, E, and G) LYVE-1^+^ lacteals and their associated αSMA^+^ cells do not express α~1~ receptors (C), but the lacteals express β~2~ receptors (E, arrows), and the associated smooth muscle cells express M2 receptors (G, arrows). The α~1~ receptor expressing enterocytes ([@bib2]) are clearly visible (asterisk in C). Images were obtained using confocal microscopy.Scale bars represent 50 μm (B, D, and F) and 25 μm (C, E, and G). Data in (A) are presented as mean ± SD. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Even though it was not detected at the RNA level in cultured human LECs, we next performed whole-mount staining for the muscarinic receptor M~2~. We found expression of M~2~ receptors by smooth muscle cells of the flank and mesenteric collector and of the lacteal villi, whereas the LECs themselves only showed expression of M~2~ receptors in the collecting vessels ([Figures 1](#fig1){ref-type="fig"}F, 1G, and [S1](#mmc1){ref-type="supplementary-material"}H). As a second method, flow-cytometry studies on freshly isolated flank collector LECs were performed ([Figures S1](#mmc1){ref-type="supplementary-material"}I and S1J). Thereby, we were able to confirm the expression of α~1~ and β~2~ receptors. Additionally, but to a lower extent than β~2~ receptors, we also detected positive expression of β~1~ receptors. Due to the lack of a suitable antibody, we were unable to assess M~2~ receptor expression using this approach. Taken together, these findings reveal that LVs specifically express receptors in an organ-site-dependent manner that may enable them to respond to neurotransmitters released from the autonomic nervous system.

Nerves Are Closely Associated with LVs {#sec2.2}
--------------------------------------

In order to exert neural effects on LVs, the presence of synapses formed by nerves is required, as these represent the source of neurotransmitters. Whole-mount staining of collecting LVs from different organ sites of *Prox1-GFP* mice for the pan-neural marker TuJ1 detected nerves running along LVs ([Figure 2](#fig2){ref-type="fig"}A). Tyrosine hydroxylase (TH)-positive sympathetic nerves were detected, forming synapsin-I-positive synapses on lymphatic collectors ([Figure 2](#fig2){ref-type="fig"}B). Parasympathetic nerves are characterized by their expression of choline acetyltransferase (ChAT). We therefore performed whole-mount staining of *ChAT-GFP* mice in combination with synapsin I staining to detect synapses. Mesenteric lymphatic collectors demonstrated innervation with parasympathetic nerves ([Figure 2](#fig2){ref-type="fig"}C, zoom-in), whereas no ChAT^+^ neural structures were detected on collectors at other organ sites, such as the flank ([Figure 2](#fig2){ref-type="fig"}D).Figure 2Nerves Are Closely Associated with LVs(A) Lymphatic collectors of *Prox1-GFP* mice are closely associated with pan-neural marker TuJ1^+^ nerves (arrows).(B) Tyrosine hydroxylase (TH)^+^ sympathetic nerves run along lymphatic collectors of *Prox1-GFP* mice and form synapses (synapsin I, zoom-in).(C) Choline acetyltransferase (ChAT) GFP^+^ parasympathetic nerves, which form synapses (synapsin I), accompany mesenteric collectors (zoom-in).(D) Collectors other than mesenteric collectors show no ChAT^+^ innervation. Synapsin I staining shows the presence of other types of nerves (zoom-in). Images were obtained using confocal microscopy.Scale bars, 50 μm. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Whole-mount staining showed a close proximity of nerves (TuJ1^+^), distinguishable as either sympathetic (TH^+^) or parasympathetic (ChAT^+^), with intestinal lacteals ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2C). Synapsin I staining revealed that the nerves adjacent to lacteals also formed synapses ([Figures S2](#mmc1){ref-type="supplementary-material"}D and S2E).

Overall, these results demonstrate that autonomic nerves of different subtypes are present near LVs, indicating the possibility of a direct influence on LV function.

LECs Are Direct Targets of Neurotransmitters {#sec2.3}
--------------------------------------------

To evaluate if LECs might demonstrate downstream signaling in response to neurotransmitters, we next investigated their Ca^2+^ response *in vitro* as well as *in vivo*. This approach was chosen because activation of most muscarinic receptors and some adrenergic receptors leads to an increase of intracellular calcium as a second messenger. *In vitro* imaging of human LECs using Fluo8H was quantified with a self-written algorithm that is explained in [STAR Methods](#sec4){ref-type="sec"} and [Figure 3](#fig3){ref-type="fig"}A. We found that intracellular Ca^2+^ was increased upon treatment with NE (1 μmol/L) or isoproterenol (10 μmol/L) ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}). To evaluate the specificity of this experiment, pretreatment of cells with an antagonist was performed. Propranolol (100 μmol/L) strongly inhibited the increase of intracellular Ca^2+^ induced by isoproterenol ([Figure 3](#fig3){ref-type="fig"}B). The quantification of the percentage of activated cells was in line with the visual quantification of Ca^2+^ activation ([Figure 3](#fig3){ref-type="fig"}C).Figure 3LECs Are Direct Targets of Neurotransmitters *In Vitro*(A) Visualization of the algorithm made for Ca^2+^ quantification. After enhancing the quality of each frame (image pre-processing), each cell is detected separately and linked between consecutive frames in order to track it over the whole duration of the video (Cell Detection and Linking). For each tracked cell (Track), the fluorescence intensity over time is computed. If the signal changes notoriously over time, an activation event is recorded (Event Detection). A detailed description can be found in [STAR Methods](#sec4){ref-type="sec"}.(B) Quantification of *in vitro* Ca^2+^ imaging of human primary LECs using Fluo8H in response to different neural agonists. Each horizontal line of the bar represents a tracked cell; only activated cells are shown in gray. Fluo8H intensity is shown in grayscale, proportional to intracellular Ca^2+^.(C) Quantification of the percentage of cells reacting with an increase of Ca^2+^ upon treatment with different agonists. LCIS, live cell imaging solution; Iso, isoproterenol; Prop, propranolol. ^∗∗^p ≤ 0.01. Data in are presented as mean ± SD; n = average per well of cells. Individual cells can be seen [Figure S3](#mmc1){ref-type="supplementary-material"}.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

For *in vivo* imaging, *Cx40 GCaMP2* transgenic mice were used ([@bib42]). These mice express the calcium indicator *GCaMP2* under control of the connexin 40 promoter and provide a dynamic readout of GFP signal intensity that is proportional to the intracellular calcium concentration. Connexin 40 is expressed in arterial endothelial cells and to a lesser degree in LECs. In these mice, we infused 0.5 μL of 10 μmol/L 20 kDa PEG-IRDye680 (P20D680) near-infrared (NIR) tracer ([@bib35]) either alone or mixed with adrenergic or muscarinic agonists into the inguinal lymph node ([Figure 4](#fig4){ref-type="fig"}A) and evaluated a region of interest over the efferent collecting LV. The tracer was used to define the time point when the infused agonist arrives in the region of interest. Ca^2+^ fluxes in the LECs were analyzed by measuring changes in the GFP intensity before arrival of the tracer compared to the time point of arrival ([Figure 4](#fig4){ref-type="fig"}B). When tracer alone was infused, the GFP intensity dropped due to the volume-induced dilation of the collecting vessel ([Figure 4](#fig4){ref-type="fig"}C). When the muscarinic agonist ACh (27.5 μmol/L) was infused with the tracer, a clear transient spike in GFP intensity was observed ([Figure 4](#fig4){ref-type="fig"}C). The same was observed for the β adrenergic agonist isoproterenol (10 μmol/L).Figure 4LECs Are Direct Targets of Neurotransmitters *In Vivo*(A) Schematic overview of *in vivo* Ca^2+^ imaging using *Cx40 GCaMP2* mice. The flank collector was used for imaging. Ingl LN, inguinal lymph node; ROI, region of interest.(B) Representative example of GCaMP2 intensity (top) measurement while a mixture of pegylated NIR dye and acetylcholine was infused into the inguinal lymph node. At time of arrival of the dye (bottom), there is a visible peak of the GCaMP2 expression (frame 50, blue line).(C) The GCaMP2 signal intensity at time point of arrival of the dye in the imaged section was normalized to the signal intensity before arrival of the dye. Differences are shown as percent change of the baseline signal intensity. ^∗∗^p ≤ 0.01. Data are presented as mean ± SD; n = 3 mice.

Together, these results indicate that LECs might represent direct targets of neurotransmitters.

The Autonomic Nervous System Regulates Lymphatic Contractility *In Vivo* {#sec2.4}
------------------------------------------------------------------------

To investigate the regulation of LV contractility by the autonomic nervous system *in vivo*, we used a previously described method ([@bib7]). In brief, after the infusion of 0.5 μL of the P20D680 NIR dye into the inguinal lymph node, the flank collector becomes visible and contractile activity can be imaged ([Figure 5](#fig5){ref-type="fig"}A). Over a period of 8 min, the fluorescent intensity of the tracer in the vessel is imaged, which corresponds to diameter changes of the vessel ([Figure 5](#fig5){ref-type="fig"}B) and enables quantification of the contractility using a custom-made algorithm ([@bib7]). After the first 2 min, a topical treatment was applied. We quantified contraction frequency, amplitude, and pumping score, which is the product of frequency and amplitude, after treatment with a range of muscarinic, α-adrenergic, and β-adrenergic agonists and antagonists.Figure 5The Autonomic Nervous System Regulates Lymphatic Contractility *In Vivo*(A) Schematic overview of *in vivo* imaging of flank collector contractility.(B) Representative example of measured NIR-dye intensity in the flank collector over time; topical treatment was done at time point 2 min.(C--E) Effects of topical treatment with neural agonists and antagonists on lymphatic contraction frequency (C), amplitude (D), and pumping score (E). Shown are the post-treatment values as a percentage of pretreatment values for mice under injection anesthesia (ketamine, xylazine, and acepromazine).(G--I) Same is shown for mice under isoflurane: changes in frequency (G), amplitude (H) and pumping score (I).(F and J) Quantification of the tonic contraction of the flank collector upon treatment with neural agonists and antagonists under injection anesthesia (F; ketamine, xylazine, acepromazine) and isoflurane (J).(K and L) Isoproterenol-mediated phosphorylation of eNOS, as assessed (K) and quantified (L) by western blot. VEGF-A was used as positive control. The western blot shown is a representative example of at least three independent experiments.^∗^p \< 0.05, ^∗∗^p ≤ 0.01. Data are presented as mean ± SD. (C--F) n = 8 vessels for PBS, and n = 6 vessels for all other treatments. (G--J) n = 4 vessels per treatment. (K and L) n = 1. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Comparing the post-treatment period (minutes 4--7) with the pretreatment period (first 2 min), potent effects of several agonist and antagonists were found ([Figures 5](#fig5){ref-type="fig"}C--5E, [S5](#mmc1){ref-type="supplementary-material"}C, and [S5](#mmc1){ref-type="supplementary-material"}D). There was a strong increase of contractile activity upon treatment with the muscarinic agonist carbachol (2 μmol/L; amplitude 212.62% of pre-value; pumping score 317.67% of pre-value). Conversely, antagonization of the muscarinic system by atropine (100 nmol/L) reduced the contraction activity significantly (frequency 57.63% of pre-value; pumping score 44.26% of pre-value). For the adrenergic system, we detected reduced contractility upon treatment with the unspecific β-adrenergic agonist isoproterenol (10 μmol/L; frequency 45.1% of pre-value). To determine if this effect was mediated by β~1~ or β~2~ receptors, the specific β~1~ agonist denopamine and the specific β~2~ agonist salbutamol (both at 1 μmol/L) were studied. Only salbutamol induced an inhibitory effect (frequency 65.29% of pre-value), indicating that the effect is predominantly mediated by β~2~ receptors. Treatment with agonists at two additional concentrations (0.1 and 10 μM) also showed no significant effect of the β1 agonist, while the higher concentration of the β2 agonist showed a strong trend of reduced frequency (62.88% of pre-value) ([Figure S5](#mmc1){ref-type="supplementary-material"}B). The unspecific β adrenergic antagonist propranolol (10 μmol/L) exhibited a trend to activate the contraction activity (frequency 115.07% of pre-value, amplitude 171.55% of pre-value, pumping score 197.86% of pre-value). To ensure specificity of the β2 agonist, competitive blocking studies were performed. After the exposed vessels were treated at t = 2 min, either PBS or the β2 antagonist were added at t = 4 min, and the vessels' post-treatment was assessed at t = 6--9 min. While PBS treatment had no effect on the reduction of contractility, treatment with the β2 antagonist neutralized the effect of the initial β2 agonist, resulting in no change in contractility ([Figure S5](#mmc1){ref-type="supplementary-material"}A).

The α-adrenergic system has been reported to induce contractility in isolated LVs ([@bib32], [@bib44]). In line with these results, we found a reduced contraction activity upon antagonization of the α adrenergic system using phentolamine (10 μmol/L; amplitude 62.42% of pre-value; pumping score 46.79% of pre-value; [Figures 5](#fig5){ref-type="fig"}D and 5E). Phentolamine was dissolved in DMSO, reaching a final DMSO concentration of 0.01%. In previous studies, we confirmed that this concentration of DMSO had no effect on the contraction activity ([@bib7]). Surprisingly, we could not detect any effect of the α-adrenergic (and, with much lower affinity, β-adrenergic) agonist NE. This lack of response was most probably due to the usage of the injection anesthesia (ketamine, xylazine, and acepromazine) that contained α agonists itself. To investigate this hypothesis, we repeated the adrenergic treatments with mice under isoflurane anesthesia ([Figures 5](#fig5){ref-type="fig"}G--5I and [S6](#mmc1){ref-type="supplementary-material"}). We confirmed the inhibiting effect of the α antagonist phentolamine (10 μmol/L; amplitude 19.87% of pre-value), while the DMSO control showed no significant effect. More importantly, we found a strong activating effect of NE (1 μmol/L; frequency 277.29% of pre-value), indicating that the lack of effect in the previous experiments was due to the choice of anesthesia. To investigate whether the results observed after treatment with other mediators might also have been affected by the injection anesthesia, we next treated collecting LVs in mice anesthetized with isoflurane with β adrenergic compounds. Isoproterenol (10 μmol/L) induced comparable effects (frequency 10.32% of pre-value) and propranolol (10 μmol/L) had only minor effects on the contractility (frequency 66.63% of pre-value) ([Figures 5](#fig5){ref-type="fig"}G--5I).

Overall, these *in vivo* experiments identified a strong impact of neurotransmitters on the contraction activity of lymphatic collectors in mice.

β-Adrenergic Stimulation Regulates LV Tone by eNOS Phosphorylation {#sec2.5}
------------------------------------------------------------------

Besides the effects on phasic contractions, we next investigated whether treatment with neurotransmitters might also mediate changes in vessel tone, since previous studies indicated that NE increases the vessel tone of lymphatic collectors from various organ sites by inducing vasoconstriction ([@bib13], [@bib32], [@bib41]). While mice under injection anesthesia did not show any effect of NE on the vessel tone ([Figure 5](#fig5){ref-type="fig"}F), in line with the lack of any response in phasic contractions, the vessel tone was increased in mice under isoflurane anesthesia ([Figure 5](#fig5){ref-type="fig"}J). We observed a decrease in vessel tone (vasodilation) upon treatment with isoproterenol, independent of the anesthesia regimen used. As a potential mediator of vasodilation, we next investigated the phosphorylation state of eNOS in LECs upon treatment with β-adrenergic agonists by western blot and found an increased phosphorylation after treatment with isoproterenol ([Figures 5](#fig5){ref-type="fig"}K and 5L). Thus, treatment with isoproterenol may lead to increased NO production in LECs. The released NO acts on the nearby smooth muscle cells, induces their relaxation, and, therefore, leads to a dilation of the collecting LV.

Tumor-Draining Lymphatic Collectors Contract More Actively {#sec2.6}
----------------------------------------------------------

B16F10 melanomas were grown in the flank skin of *Prox-1 GFP* mice ([Figure 6](#fig6){ref-type="fig"}A). When tumors reached 12 mm in one dimension, tumor-draining LVs were imaged *in vivo*. As reported by many studies ([@bib34], [@bib39], [@bib40]), we found that several LVs were expanded in the vicinity of the flank collector, demonstrating the direct activating effect of the tumor on the lymphatic vasculature ([Figure 6](#fig6){ref-type="fig"}B). TuJ1 staining of the affected vessels showed a denser innervation ([Figures 6](#fig6){ref-type="fig"}C and 6D). In line with this finding, the tumor-draining flank collectors had a higher baseline contraction activity ([Figure 6](#fig6){ref-type="fig"}E). Based on the results obtained under physiological conditions, we next investigated whether treatment with distinct neurotransmitters might inhibit the contractility of tumor-draining LVs. Indeed, atropine, phentolamine, and, most potently, isoproterenol reduced the pumping score significantly ([Figures 6](#fig6){ref-type="fig"}F and [S6](#mmc1){ref-type="supplementary-material"}).Figure 6Tumor-Draining Lymphatic Collectors Contract More Actively(A) Growth of intradermally injected B16F10 tumors was measured over time using a caliper (n = 7 mice).(B) Overview picture of the flank area in a naive (left) and a tumor-bearing *Prox1-GFP* mouse (right). In the vicinity of the flank collector (asterisk), additional lymphatic collectors were formed draining the tumor.(C) Compared to physiological LVs (left), tumor-draining vessels show denser innervation, visualized with the pan-neural marker TuJ1 (Prox1-GFP staining, green; αSMA, yellow).(D) Quantification of innervation density (nerve length/vessel length).(E) Tumor-draining LVs show higher baseline activity than the respective vessels in non-tumor-bearing mice with regard to frequency, amplitude, and pumping score.(F) Contractility of tumor-draining vessels can be inhibited by atropine, phentolamine, and isoproterenol.^∗^p \< 0.05, ^∗∗^p ≤ 0.01, and ^∗∗∗^p ≤ 0.001. Scale bars represent 500 μm (B) and 25 μm (C). Data represent mean ± SD, and dots in (D) and (E) represent vessels. (F) n = 4 vessels per treatment. BV, blood vessel. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

In this study, we provide the first comprehensive *in vivo* characterization of the regulation of LV contractility by agonists and antagonists of the autonomic nervous system. Our findings reveal that both smooth muscle cells and endothelial cells of LVs express distinct neurotransmitter receptors and that nerves and synapses are in contact with these vessels. We identified specific functions of the sympathetic and the parasympathetic nervous system with regard to LV contraction and confirmed the distinct activation of signaling in LECs by Ca^2+^ imaging *in vitro* and *in vivo*. The studies of tumor-draining LVs revealed their increased innervation and contraction activity and also identified neurotransmitters that may inhibit the activity of tumor-draining LVs.

In our investigation of the expression of neurotransmitter receptors in LECs, we found that cultured human LECs only express β-adrenergic receptors, whereas, in addition, both α~1~-adrenergic and M~2~-muscarinic receptors were found on murine collecting LVs by whole-mount staining and flow-cytometry analysis. The lack of expression of several of these receptors *in vitro* might indicate a change of the expression profile of LECs under the *in vitro* culture conditions, in agreement with previous studies ([@bib1], [@bib46]). In addition, these differences might also represent vessel-type-specific expression patterns, since the cultured human LECs were isolated from the skin and might be more representative of LECs originating from capillaries and not from collecting LVs. Consistent with this concept, murine lacteal LECs, representing cells of specialized intestinal lymphatic capillaries, also only express β-adrenergic receptors. However, species-associated differences between humans and mice cannot be ruled out as well. Confirmation for the differently expressed receptors in LECs *in vitro* compared to the *in vivo* situation was obtained by the Ca^2+^ imaging studies, since cultured cells only responded to β agonists, whereas there was also a response to the muscarinic agonist ACh *in vivo*.

Our finding of an organ-specific expression pattern of neurotransmitter receptors may provide an explanation for the previously reported discrepancies of NE effects on LV function. While contractility was increased in *ex vivo* preparations of peripheral collecting LVs from different species (including human) after exposure to NE ([@bib13], [@bib32], [@bib41], [@bib44]), in agreement with our *in vivo* studies in mice, a recent study reported a diminished contraction activity of intestinal lacteals after NE treatment ([@bib4]). Our findings indicate that the opposing effects of the same adrenergic agonist can be explained by the absence of α-adrenergic receptors on the lacteals. Thus, NE (being an α-adrenergic agonist and, with much lower affinity, also a β-adrenergic agonist) likely acts as a β agonist in lacteals, leading to reduced contractility, whereas it promotes contractions in lymphatic collectors via the α-adrenergic receptors. This organ-specific response to NE makes sense physiologically, since under systemic stress conditions, enhanced return of peripheral lymph fluid together with reduced energy expense for the gastrointestinal lipid transport might be advantageous.

A major conclusion from our studies is that muscarinic and α-adrenergic agonists activate the contractility of collecting LVs, whereas β~2~-adrenergic agonists reduce the contraction frequency. The activating effect mediated by NE is in agreement with previous *ex vivo* studies ([@bib18], [@bib20], [@bib26], [@bib27], [@bib44]). However, whereas some of these studies indicated that this effect is mediated via α~2~ receptors ([@bib18]), others suggested that both α~1~ and α~2~ receptors are involved ([@bib20]). Our findings that there are profound differences in the expression patterns of neurotransmitter receptors on different types of LVs indicate that some of the reported differences might relate to organ-specific responses to neurotransmitters. In support of this concept, LVs isolated from the liver and lungs of pigs showed decreased contraction and were dilated upon ACh treatment ([@bib15], [@bib18]), similarly to isolated thoracic ducts of dogs ([@bib29]). By contrast, in rat mesenteric vessels ([@bib14]), operation-induced vagotomy resulted in a reduced contraction rate, indicating an activating role of the parasympathetic nervous system with its main neurotransmitter, ACh, in line with the contraction-inducing effects of ACh in bovine mesenteric LVs ([@bib30]). Another possible explanation for these opposing effects of ACh might be the ratio of muscarinic receptors expressed on LECs versus smooth muscle cells. If muscarinic receptors are expressed predominantly on smooth muscle cells, then their activation likely induces LV contraction, whereas binding of ACh on muscarinic receptors on LECs induces NO release ([@bib36]), resulting in vessel dilation and reduced contractility. Thus, a detailed characterization of the neurotransmitter receptor expression profiles of human LVs from different organs, as well as from model organisms such as the mouse, is needed to better understand the organ- and species-specific effects of the autonomic nervous system.

Our data indicate that the choice of anesthesia is of great importance for the design and interpretation of functional studies of LV contractility. We were unable to detect the activating effects of the α-agonist NE when using an injection anesthesia regimen that contained the α-agonist xylazine, thus masking the effects of NE on LV contractility. By contrast, NE induced an increased LV contraction frequency under isoflurane anesthesia. However, this anesthesia regimen turned out to be associated with a general depression of LV contractions. Thus, a thorough investigation of different anesthesia regimens for functional *in vivo* studies of LVs would be helpful to ensure a better cross comparison of published work.

The results of our *in vivo* studies are in agreement with the improvement of secondary lymphedema after therapeutic inhibition of the sympathetic nervous system in patients after breast cancer surgery (E. [@bib6]) and gynecologic-cancer-related surgery ([@bib47]). In these clinical settings, the treatment blocks the complete sympathetic nervous system locally. Thus, one might speculate that the parasympathetic nervous system, which is left intact after the treatment, promotes LV contractions, resulting in improvement of the lymphedema.

One should keep in mind that the autonomic nervous system influences both lymphatic and blood vessels, indicating that therapies aimed at modulating blood vessel functions might also impact the function of the lymphatic vascular system. As an example, the long-term usage of β blockers for hypertension might negatively influence the balanced system of physiological lymphatic contractions. Similarly, while β~2~ agonists are successfully used to induce bronchodilation in asthma patients, they might reduce the contractility of lymphatics of the lung and increase NO release by LECs, potentially leading to a reduced fluid clearance of the lung tissue.

To our knowledge, our studies identified for the first time that the expanded tumor-draining LVs have a higher innervation density, which might contribute to the observed increase in contractility of the preexisting and newly formed LVs. The increased contractility of tumor-draining LVs is in agreement with a previous study in mice where increased smooth muscle cell coverage was also detected ([@bib17]). Together, these findings reveal that tumors not only induce LEC proliferation and lymphangiogenesis but also profoundly change the anatomical structure and function of tumor-draining LVs. Our findings that specific agonists and antagonists of the autonomic nervous system reduce the contractility of tumor-draining LVs might be of potential relevance for clinical cancer therapy. In the future, targeted long-term treatment of tumor-draining LVs would be needed to investigate whether the inhibition of lymphatic contractility ultimately results in reduced tumor growth and metastasis. At the same time, these studies could also address possible negative effects of an increased interstitial pressure induced by such long-term treatments, including potentially reduced tumor tissue penetration of therapeutic compounds.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**alpha-1 adrenergic receptorSanta Cruzcat\# sc-1477; RRID:[AB_630854](nif-antibody:AB_630854){#interref20}beta-1 adrenergic receptorabcamcat\# ab3442; RRID:[AB_10890808](nif-antibody:AB_10890808){#interref25}beta-2 adrenergic receptorabcamcat\# ab13989; RRID:[AB_300816](nif-antibody:AB_300816){#interref30}muscarinic acetylcholine receptor 2abcamcat\# ab109226; RRID:[AB_10858602](nif-antibody:AB_10858602){#interref35}muscarinic acetylcholine receptor 3Santa Cruzcat\# sc-9108; RRID:[AB_2291779](nif-antibody:AB_2291779){#interref40}Synapsin-1Invitrogencat\# 51-5200; RRID:[AB_87668](nif-antibody:AB_87668){#interref45}Tyrosine HydroxylaseR&Dcat\# AF7566Tyrosine HydroxylaseInvitrogencat\# P21962; RRID:[AB_2539844](nif-antibody:AB_2539844){#interref50}III beta TubulinBioLegendcat\# 801201; RRID:[AB_2313773](nif-antibody:AB_2313773){#interref55}GFPAvescat\# GFP-1010; RRID:[AB_2307313](nif-antibody:AB_2307313){#interref60}CD31BD Biosciencecat\# 550274; RRID:[AB_393571](nif-antibody:AB_393571){#interref65}alpha smooth muscle actinSigma-Aldrichcat\# C6198; RRID:[AB_476856](nif-antibody:AB_476856){#interref70}LYVE-1AngioBiocat\# 11-034LYVE-1ReliaTechcat\# 103-M130eNOSThermoFishercat\# PA1-037; RRID:[AB_325774](nif-antibody:AB_325774){#interref75}Phospho-eNOS (Ser1177)CellSignalingcat\# 9571; RRID:[AB_329837](nif-antibody:AB_329837){#interref80}TubulinSigma-Aldrichcat\# T9026V; RRID:[AB_477593](nif-antibody:AB_477593){#interref85}goat Alexa 594Invitrogencat\# A-11058; RRID:[AB_2534105](nif-antibody:AB_2534105){#interref90}rabbit Alexa 488Invitrogencat\# A-21206; RRID:[AB_2535792](nif-antibody:AB_2535792){#interref95}rabbit Alexa 647Invitrogencat\# A-31573; RRID:[AB_2536183](nif-antibody:AB_2536183){#interref100}chicken Alexa 488Jackson ImmunoResearchcat\# 703-545-1551sheep Alexa 594Invitrogencat\# A-11016; RRID:[AB_2534083](nif-antibody:AB_2534083){#interref105}rat Alexa 488Invitrogencat\# A-21208; RRID:[AB_2535794](nif-antibody:AB_2535794){#interref110}rabbit HRPGE Healthcarecat\# NA9340V; RRID:[AB_772191](nif-antibody:AB_772191){#interref115}mouse HRPGE Healthcarecat\# NA931; RRID:[AB_772210](nif-antibody:AB_772210){#interref120}**Chemicals, Peptides, and Recombinant Proteins**DL-Norepinephrine hydrochlorideSigma-aldrichcat\# A7256Phentolamine hydrochlorideSigma-aldrichcat\# P7547Atropine sulfate salt monohydrateSigma-aldrichcat\# A0257CarbacholMilliporecat\# 212385(−)-Isoproterenol hydrochlorideSigma-aldrichcat\# I6504(±)-Propranolol hydrochlorideSigma-aldrichcat\# P0884R(-)-DenopamineSigma-aldrichcat\# D7815(±)-Metoprolol (+)-tartrate saltSigma-aldrichcat\# M5391SalbutamolSigma-aldrichcat\# S8260ICI-118,551 hydrochlorideSigma-aldrichcat\# I127**Experimental Models: Cell Lines**MeWoSigma-Aldrichcat\# 93082609human bronchial smooth muscle cellsScienCellcat\#3400B16F10ATCCCRL-6475, RRID:CVCL_0159human dermal lymphatic endothelial cellsGroup Prof. DetmarN/A**Experimental Models: Organisms/Strains**Prox-1 GFPDr. Young-Kwon Hong, University of Southern CaliforniaI. [@bib5]ChAT GFPJackson LaboratoriesStrain No 007902Cx40^BAC^-GCaMP2Dr. Michael Kotlikoff, Cornell University and the CHROMus mouse resourceR24HL120847C57BL/6JJackson LaboratoriesStrain No 000664**Oligonucleotides**See [Table S4](#mmc1){ref-type="supplementary-material"} for used primersN/A**Software and Algorithms**Quantification algorithmsFor full MATLAB codes please see [STAR Methods](#sec4){ref-type="sec"}.N/A

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Michael Detmar (<michael.detmar@pharma.ethz.ch>).

Experimental Models and Subject Details {#sec4.3}
---------------------------------------

### Cell culture {#sec4.3.1}

Primary male human LECs ([@bib19]) were cultured under standard culture conditions (37°C and 5% CO~2~) on collagen (Advanced BioMatrix) coated dishes (50 μg/mL) in EBM medium (Lonza) containing 20% FBS (GIBCO), 1% penicillin/streptomycin (GIBCO), 2 mmol/L L-glutamine (GIBCO), 25 μmol/mL cAMP (Sigma-Aldrich) and 10 μg/mL hydrocortisone (Sigma-Aldrich).

Human bronchial smooth muscle cells were purchased from ScienCell and cultured under standard conditions in Smooth Muscle Cell Medium 2 containing the Supplemental Mix (both PromoCell). MeWo cells (Sigma Aldrich) were cultured under standard culture conditions in DMEM containing pyruvate (GIBCO) and 10% FBS.

### Mice {#sec4.3.2}

Mice were group housed in IVC cages containing a mouse house and environmental enrichment under pathogen-free conditions. Mice were not involved in previous procedures. Mice of both genders were used at the age of 7-20 weeks for organ collection and 7-12 weeks for *in vivo* imaging. *Prox1-GFP* mice on the C57BL/6J background, used for clear visualization of LVs in whole mounts and tumor studies, were a kind gift of Dr. Young-Kwon Hong, University of Southern California ([@bib5]). *B6.Cg-Tg(RP23-268L19-EGFP)2Mik/J* (ChAT-GFP, strain number 007902) mice and *C57BL/6J* mice were purchased from Jackson Laboratories, Bar Harbor, ME. *Cx40*^*BAC*^*-GCaMP2* mice ([@bib42]) were obtained from Dr. Michael Kotlikoff, Cornell University and the CHROMus mouse resource (R24HL120847).

For organ collection at the end of imaging, mice were euthanized with an overdose of anesthesia (160 mg/kg ketamine; 0.4 mg/kg medetomidine) followed by cervical dislocation and opening of the chest cavity. All experiments were approved by Kantonales Veterinaeramt Zurich (protocols: 11/2012, 12/2015).

Method Details {#sec4.4}
--------------

### LEC treatment *in vitro* {#sec4.4.1}

LECs were incubated in EBM containing 1% FBS overnight (starvation medium). Compounds of interest ([Table S1](#mmc1){ref-type="supplementary-material"}) were added in starvation medium. Antagonists were added 30 min before treatment of the cells with the corresponding agonist. 15 min after agonist addition, total protein was extracted and protein concentration was measured using a Pierce BCA assay (ThermoFisher).

### Western blotting {#sec4.4.2}

Equal amounts of denaturized protein were loaded per slot, using pre-cast NuPage gels (ThermoFisher). A Mini Gel Tank system was used to run and blot the gels (ThermoFisher) according to manufacturer's instructions. After blocking the membranes, protein was detected using specific primary antibodies ([Table S2](#mmc1){ref-type="supplementary-material"}) and HRP-conjugated secondary antibodies ([Table S3](#mmc1){ref-type="supplementary-material"}). ECL was used for visualization using an Agfa Curix Developer. Quantification of phosphorylation was performed using FIJI ([@bib38]).

### RNA isolation and qPCR {#sec4.4.3}

For RNA extraction, the NucleoSpin RNA kit from Macherey-Nagel was used according to the manufacturer's instructions. RNA was reverse transcribed with the High Capacity cDNA kit (Applied Biosystems/ThermoFisher). qPCR analyses were done in triplicate using SYBRGreen (Roche) on a 7900 HT Fast Real-Time PCR System (Applied Biosystems). The following genes were analyzed: *ADRA1A, ADRA1B, ADRA1d, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, ChRM1, ChRM2, ChRM3, ChRM4* and *ChRM5* (for primers see [Table S4](#mmc1){ref-type="supplementary-material"}). For normalization, *GAPDH* expression was analyzed.

### Tissue digestion and FACS analysis {#sec4.4.4}

For FACS analysis of LECs, the flank collectors were dissected, minced, and digested in a collagenase solution \[530 u/mL Collagenase II (Worthington), 0.744 u/mL Elastase (Worthington),5 u/mL DNase I (Roche)\] for 70 min at 37°C. The digested tissue was passed through a cell strainer, washed and labeled with antibodies (see [Tables S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}) for 30 min at 4°C, followed by incubation of secondary antibody for 30 min at 4°C. Cells were stained for Zombie-NIR used for life/dead discrimination. After washing, cells were resuspended in FACS buffer for acquisition. Data were acquired on a FACS ARIA (BD) and analyzed using FlowJo v10.2 software (Treestar Inc.).

### Imaging of flank collector contractions {#sec4.4.5}

The contractility of the flank collecting LV was analyzed as described ([@bib7]). In brief, mice were anesthetized using a combination of xylazine (20 mg/ kg, Rompun® 2%, Provet), ketamine (100 mg/kg, Ketasol®, Graeub) and acepromazine (3 mg/kg, Prequillan®, Arovet) or with isoflurane (2.5%, Attane®, Provet). After loss of a detectable response to toe pinches, mice were fixed on a silicone dish and the flank collector was exposed. Tissue was kept moist by applying warm PBS and mice were kept on a heating pad during the imaging. Cannulation of the inguinal lymph node enabled a 0.5 μL infusion of 10 μmol/L P20D680 dye into the node and thereby visualization of the flank collector. For infusion, a pump (PHD2000, Harvard Apparatus, Cambridge, MA) was used, connected to a custom-made catheter using polyethylene PE-10 tubing (SCI, Lake Havasu City, AZ) and a 30-g needle. After stabilization of the contractility, videos of 8 min (9 min for the specificity testing) duration were acquired. Local topical treatment of the flank collector was done at time point 2 min (compound information see [Table S1](#mmc1){ref-type="supplementary-material"}). For the specificity testing, the second treatment was topically added at time point 4 min. Videos were acquired using either a Zeiss StereoLumar.V12 stereomicroscope with AxioVision (Carl Zeiss, Feldbach, Switzerland) software and a Photometrics Evolve 512 camera or a Zeiss AxioZoom.V16 fluorescence zoom microscope with Zen Pro (Carl Zeiss) software and a QImaging OptiMOS sCMOS camera (QImaging, Surrey, Canada) in combination with a light-emitting diode illumination system pE-4000 (CoolLED Ltd, Andover, UK) and filters for Cy5 (Carl Zeiss). The contractility was quantified using a previously described algorithm ([@bib7]).

Mice were allocated randomly to a specific treatment. Group size was evaluated after first pilot studies using power-analysis. Exclusion criteria for an infused vessel were: complete coverage with fat or visible luminal obstruction of the vessel induced by the infusion by e.g., blood coagulates.

### *In vivo* Ca^2+^ imaging {#sec4.4.6}

Flank collectors of *Cx40*^*BAC*^*-GCaMP2* mice were exposed. Infusion of either 0.5 μL of 10 μmol/L P20D680 tracer or a mixture of tracer with agonists was performed into the inguinal lymph node. During infusion, a video of the flank collector was acquired using a custom built 2-photon laser-scanning microscope. For quantification of a possible Ca^2+^ peak, mean intensity of the GCaMP2 signal was measured over the vessel wall during the video ([Figure 5](#fig5){ref-type="fig"}A). Specific compounds were randomly allocated to mice.

### *In vitro* Ca^2+^ imaging {#sec4.4.7}

The Fluo8H, AM (AAT Bioquest, cat-no. 21091) was used according to the manufacturer's instructions. In brief, Fluo8H stock solution (1.14 mol/L) was prepared by adding 1.5% Pluronic and 2.4% DMSO in PBS. Cells were incubated in EBM containing 1% FBS for 4h, Fluo8H 1:500 in starvation medium was added and cells were incubated for 30 min at 37°C, followed by 10 min at room temperature. Cells were washed twice with Live Cell Imaging Solution (Molecular Probes). Imaging of cells was performed in Live Cell Imaging Solution; compounds were added in the same volume of live cell imaging solution as the cells were cultured in, using 2x treatment solutions. Imaging was performed using a fluorescent microscope (Nikon Eclipse Ti-E, Tokyo, Japan) in combination with a Hamamatsu ORCA-Flash4.0 CCD camera (Hamamatsu, Japan). FITC fluorescence videos were acquired and quantified as stated below.

### Whole mount stainings {#sec4.4.8}

Vessels or pieces of small intestine were dissected out of 7- to 20-week-old mice of either gender. The small intestine samples were cut open longitudinally to give access to villi. Samples were fixed with 4% PFA for 2h at 4°C or for 1h in 100% methanol at 4°C. After washing in PBS, tissues were incubated in 0.2% BSA, 5% donkey serum, 0.1% Triton-X in PBS for 3h at 4°C. Primary antibodies were incubated over night at 4°C. After washing in 0.1% Triton X in PBS, secondary antibodies were applied in 0.1% Triton X in PBS for 2h at room temperature or at 4°C for the small intestine. After several washes in PBS, tissues were mounted using Vectashield (Vector) for confocal imaging. The antibodies used are listed in [Tables S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}. Whole mount pictures were acquired using a LSM 780 FCS confocal microscope and ZEN software (Zeiss, Jena, Germany) and processed with FIJI. Positive control stainings for the neurotransmitter receptors are as follows: α~1~-positive enterocytes are visible in [Figure 1](#fig1){ref-type="fig"}C, β~1~-positive heart tissue is provided in [Figure S1](#mmc1){ref-type="supplementary-material"}D, β~2~-positive blood vessels are visible in [Figure 1](#fig1){ref-type="fig"}D and M~2~-positive liver tissue is provided in [Figure S1](#mmc1){ref-type="supplementary-material"}E.

### B16F10 melanoma studies {#sec4.4.9}

Male *C57BL/6J* mice of 7 weeks were bilaterally injected intradermally with 10^5^ B16F10 tumor cells in the flank skin. Tumor growth was monitored by size measurements using a caliper. When tumors reached 12 mm in one dimension, tumor-draining LVs were imaged *in vivo*. Mice were randomly assigned to compound treatments.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Quantification of innervation {#sec4.5.1}

Overall length of nerves covering vessels was measured manually in FIJI and divided by the length of the LV.

### Statistical analyses {#sec4.5.2}

All statistical analyses were performed using the GraphPad Prism 5 software. Data are shown as means ± SD, information on exact value and representation of n can be found in the respective figure legends. For comparison of more than two groups, one-way ANOVA with Bonferroni post-test was used for normally distributed data. For quantifications from *in vivo* flank imaging, a paired two-tailed Student's t test was used for normal distributed data. A Mann-Whitney test was used for the comparison of two groups if the data was non-normal distributed, tested by a Shapiro-Wilk test. A p value of p \< 0.05 was considered significant (p \< 0.05 ^∗^, p ≤ 0.01 ^∗∗^, p ≤ 0.001^∗∗∗^).

Data and Software Availability {#sec4.6}
------------------------------

### Quantification of low frequency contractions {#sec4.6.1}

Experiments performed with isoflurane resulted in a much lower contraction activity which could not be analyzed with the previously developed algorithm ([@bib7]). Therefore, a new algorithm was developed ([Figure S4](#mmc1){ref-type="supplementary-material"}). In order to determine the characteristics of the peaks (i.e., amplitudes and periodicity) of the measured fluorescence signal, a MATLAB (MathWorks Inc., Natick MA, USA) function with a graphical user interface was developed that performs the signal processing in a semi-automatically manner. The user selects the peaks $\left( \alpha_{i} \right)$ of the fluorescence signal manually and based on these selected values, the absolute amplitudes$\ \left( A_{j}^{abs} \right)$, relative amplitudes $\left( A_{j}^{rel} \right)$ and the frequency $\left( F_{j} \right)$ are then calculated automatically. These parameters were calculated according to the formulas$$A_{j}^{abs} = \ \left| {M_{j} - \alpha_{i + 1}} \right|,$$$$A_{j}^{rel} = \ 100\  \times \ \ \left( {{A_{j}^{abs}/M_{j}}\ } \right),$$$$F_{j} = \ 1/P_{j},$$with $M_{j}$ the baseline value of each peak according to $M_{j} = \ \alpha_{i} + \left( {\alpha_{i + 2} - \ \alpha_{i}} \right)/2$ in case of $\alpha_{i + 2} > \ \alpha_{i}$ or $M_{j} = \ \alpha_{i + 2} + \left( {\alpha_{i} - \ \alpha_{i + 2}} \right)/2$ in case of $\alpha_{i + 2} < \ \alpha_{i}$, and $P_{i}$ the time-difference between the two peaks $\alpha_{i}$ and $\alpha_{i + 1}$ with the first peak assigned to $i = 1\ $and the second to $i = 2$ (and so on). For a visualization of the mathematical nomenclature used, see [Figure S4](#mmc1){ref-type="supplementary-material"}. The formulation ensures that the amplitude and periodicity values are also calculated correctly in case the signal contains negative peaks, or a mixture of positive and negative peaks.

### MATLAB Code {#sec4.6.2}

function \[Amplitude_abs, Amplitude_rel, Period, Frequency\] = AnalyzePeaks_Ampl_Freq_v2(x,f_s)% Function to analyze a time-series regarding the characteritics of the% peaks (i.e., amplitudes, period)% \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_% For Steven Proulx and Samia Bachmann, ETH.% May 2017 \| Felix Scholkmann \| Version 2%\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_% INPUT% x: signal to analyze% f_s: sampling frequency in Hz% OUTPUT% Amplitude_abs: absolute amplitude values (first value: median, second value: inter quantile range, IQR)% Amplitude_rel: relative amplitude values (first value: median, second value: inter quantile range, IQR)% Period: period values \[in seconds\] (first value: median, second value: inter quantile range, IQR)% Frequency: frequency values \[in 1/min\] (first value: median, second value: inter quantile range, IQR)% important:% The input signal (x) must contain at least 3 peask (i.e., at least 9% points needs to be selected from the signal). This is necessary to be% able to calculate the period values.$$t=\ \left\lbrack {{1:length}\left( x \right)} \right\rbrack{./f\_ s};$$%% \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_close allscrsz = get(0,'ScreenSize'); figure('Position',\[100 50 1300 850\]);set(g*cf*., 'color', 'w'); set(g*cf*.,'defaultaxesfontsize',12)subplot(2,20,\[1,3\])% Please insert here the path to the file "Points.png"currentFolder = pwd;Path = strcat(currentFolder,'\\Points.png')img = imread(Path);image(img);set(gca, 'XTickLabelMode', 'Manual')set(gca, 'XTick', \[\])set(gca, 'YTickLabelMode', 'Manual')set(gca, 'YTick', \[\])title ('Definition','fontsize',14)fig = subplot(2,20,\[6,20\]);plot(t,x,'linewidth',2,'Color',\[0.3, 0.5, 1\])axis tightylabel('Intensity'); xlabel('Time \[s\]')title ('- \> Please select the points (\\alpha\_{i}, \\alpha\_{i+1}, \\alpha\_{i+2}, i = 1, 2, ..., \\it{N})','fontsize',14)% Get the points from the figuredisp('→ Please select the points in the figure. The press "Enter"')\[x, y\] = getpts(fig);hold onvline_red(x(2:3:end))vline_black(x(1:3:end))vline_black(x(3:3:end))n = length(x);% Calculate the amplitudesj = 1;for i = 1:3:n-2;if y(i+2) \> y(i)M(j) = (y(i+2)-y(i))/2 + y(i);A_abs(j) = abs(M(j) - y(i+1));A_rel(j) = 100 ^∗^ (A_abs(j)/M(j));j = j+1;elseM(j) = (y(i)-y(i+2))/2 + y(i+2);A_abs(j) = abs(M(j) - y(i+1));A_rel(j) = 100 ^∗^ (A_abs(j)/M(j));j = j+1;endendplot(x(2:3:end),M,'ob')plot(x(1:3:end),y(1:3:end),'ok')plot(x(3:3:end),y(3:3:end),'ok')plot(x(2:3:end),y(2:3:end),'or')% Calculate the periodsj = 1;for i = 1:3:n-4;P(j) = x(i+4)-x(i+1);j = j+1;endF = (1./(P))^∗^60; % Frequency \[1/min\]subplot(2,20,\[21:23\])bar(A_abs,'b');ylabel('Amplitude (A\_{abs}) \[absolute\]'); xlabel('Peak number')title ({'Amplitude values','\[absolute\]'},'fontsize',14)xlim(\[0,length(A_abs)+1\])subplot(2,20,\[25:27\])bar(A_rel,'b');ylabel('Amplitude (A\_{rel}) \[%\]'); xlabel('Peak number')title ({'Amplitude values','\[%\]'},'fontsize',14)xlim(\[0,length(A_rel)+1\])subplot(2,20,\[29:31\])bar(F,'r');ylabel('Frequency \[1/min\]'); xlabel('Peak number')title ({'Frequency values','\[1/min\]'},'fontsize',14)xlim(\[0,length(F)+1\])subplot(2,20,35:36)errorbar(median(A_rel),iqr(A_rel)/2,'k');hold onplot(median(A_rel),'k.','markersize',30)ylabel('Amplitude \[%\] (median +- IQR)')set(gca, 'XTickLabelMode', 'Manual')set(gca, 'XTick', \[\])title(\['A\_{rel} = ' num2str(median(A_rel)),' (' num2str(iqr(A_rel)),') %'\]);subplot(2,20,39:40)errorbar(median(F),iqr(F)/2,'k');hold onplot(median(F),'k.','markersize',30)ylabel('Frequency \[1/min\] (median +- IQR)')set(gca, 'XTickLabelMode', 'Manual')set(gca, 'XTick', \[\])title(\['F = ' num2str(median(F)),' (' num2str(iqr(F)),') 1/min'\]);% Generate output dataAmplitude_abs = \[median(A_abs), iqr(A_abs)\];Amplitude_rel = \[median(A_rel), iqr(A_rel)\];Period = \[median(P), iqr(P)\];Frequency = \[median(F), iqr(F)\];

#### Quantification of in vitro Ca^2+^ imaging {#sec4.6.3}

##### Pre-processing {#sec4.6.3.1}

An important step to restore images is denoising, which consists of reducing noise present in images but at the same time preserving objects' features such as edges, texture, etc. In this context, we have opted to use the Block-Matching and 3D filtering (BM3D) method which has shown its denoising capabilities in different datasets by preserving finer image structures ([@bib9], [@bib12]).

##### Cell Detection {#sec4.6.4}

Once the image has been pre-processed, the next step is to detect the foreground objects, i.e., cells. To do this, we use the Otsu thresholding method ([@bib33]), however instead of using a single threshold value, we adopt a two-level threshold to detect the nucleus and the cytoplasm as joint single objects.

After thresholding, small objects are further removed since they usually correspond to non-relevant objects, such as air-bubbles. In addition, since some cells may spatially be close to each other, they can end up being merged after thresholding. To cope with this issue, we use the Watershed Transform. More precisely, each segmented object is represented as a basin and the detected Watershed Lines with the distance transform are used to separate the objects.

##### Cell Linking {#sec4.6.5}

Cells are detected at each single frame separately. In order to analyze how a cell activates over time, the detected cells are first linked together over time using the Kalman filter ([@bib21]).

The Kalman filter comprises two steps: prediction and update. In the prediction step, the Kalman filter predicts the current state of the system, based on the past, through a dynamic model. In the update step, the status of the system is corrected based on the observed variables. In our case, the assignment/linking of a given cell to a specific track is based on the area of overlap of the segmented cells between consecutive frames. The Kalman Filter therefore seeks to maximize the area of overlap between cell detections over time. To obtain more robust predictions at time t, our system averages the bounding-box of the detected cells over the last four frames. To remove false positives such as air-bubbles, our system discards objects with large location changes over time. Also, short tracks are discarded for further processing. In our case, we impose the constraint that tracks shall cover at least 75% of the total length of the input video.

##### Event Detection {#sec4.6.6}

Our event detection module is versatile and besides detecting which cells got activated, it can also find out when exactly a given activation starts and ends over time. The module starts first by smoothing the cell's intensity signal (the cell-intensity track) to reduce noise. Smoothing is done with a moving average filter. Note that the smoothing step is optional and the raw signal can be directly used if so desired.

Next, the cell signals are normalized to compensate for effects such as photobleaching and also to facilitate the detection of cell activations in the subsequent steps. The normalization of a cells' signal is done by computing the average intensity $\mu_{i}$, of the detected cell at the frames before the injection time $t_{inj}$(see [Equation 1](#fd1a){ref-type="disp-formula"}).$$\mu_{i} = \frac{1}{t_{inj}}\sum\limits_{t = 0}^{t = t_{inj}}{f\left( x_{i}^{t} \right)}$$where $f\left( \  \right)$ is the mean intensity value of the collection of pixels $x_{i}^{t}$ belonging to the detected cell i at time t.

The computed mean value $\mu_{i}$ of cell i is used to normalize the signal by dividing it into the cell signal values at all later times (see [Equation 2](#fd2a){ref-type="disp-formula"}).$$\widehat{f}\left( x_{i} \right) = \frac{1}{\mu_{i}}\ f\left( x_{i}^{t} \right)\ ;\ t = \left\{ {t = t_{inj} + 1,\ ...,\ N} \right\}$$where $\widehat{f\ }$is the normalized cells' signal and N corresponds to the total number of frames. [Figure S3](#mmc1){ref-type="supplementary-material"}B shows an example of cell signals before (upper graph) and after normalization (lower graph). Detected activations above the threshold value (displayed as a black dashed line) are shaded, see next section of details of the detection algorithm.

To detect cell-activations, the normalized cell signals are thresholded. More precisely, signal values larger than a threshold value are considered as activations and values lower than the threshold are set to zero. We set this threshold value empirically to be 1.25. Note that this value can be tuned, if more detections are targeted, one can increase this value. It is important though to set this value in a conservative manner. An example of cell activation is displayed in yellow in the left graph of [Figure S3](#mmc1){ref-type="supplementary-material"}C. The thresholding step is applied for all cell signals, in such a way that all activations can be mapped as an activation map. In [Figure S3](#mmc1){ref-type="supplementary-material"}C, each row represents a single cell signal and its mean-intensity pixel values are displayed for each frame along the x axis. After thresholding the cell signals on the normalized cell signals (middle graph in [Figure S3](#mmc1){ref-type="supplementary-material"}C), a binary activation map is obtained in which cell activations are displayed as white stripes (right graph, [Figure S3](#mmc1){ref-type="supplementary-material"}C). The signal values where the cell did not activate are set to zero. In addition, to remove potential false negatives, our method first fills short gaps inside an event and also prunes short cell activations to remove false positives. In our experiments, both values were empirically set to five frames.

One important property of our method is that it detects where a cell activation starts and ends. This is done by computing the first order derivative over the binary activated signal and by looking respectively for the indexes where the derivative is respectively positive or negative (i.e., +1 or −1).

### MATLAB Code (2 parts) {#sec4.6.7}

function kalmanMultiObjectTracking(videoName)% KalmanMultiObjectTracking: this function detects a set of cells and% tracks them over time. Cell detection involves image pre-processing where% the original video frames are enhanced, e.g., denoising. The cell% detections are mapped into cell-tracks, i.e., a set of temporal% bounding-boxes for each detected cell.%% Input:%   videoName, e.g., videoName = 'hu_NE1uM_2.avi';%% Output:%   tracksHist.mat MATLAB file containing the cell-tracks.opts = getDefaultParameters(); %\# reading configuration parameters.pathInputVideo = fullfile(opts.videoPath, videoName);digitStr = '%d-';strAllMotionDigits = repmat(digitStr, 1, numel(opts.motionNoise));motionNoiseStr = sprintf(strAllMotionDigits(1:end-1),opts.motionNoise);strAllInitErrorDigits = repmat(digitStr, 1, numel(opts.initialEstimateError));initErrorStr = sprintf(strAllInitErrorDigits(1:end-1),opts.initialEstimateError);paramsDir = sprintf('%s_LRate%2.2f_visi%2.2f_age%d_invib%d_initErr%s_motNoise%s_measNoise%d\_%s_cSze%d', ...opts.motionModel, opts.learningRate, opts.trackVisibility, opts.ageThreshold, ...opts.invisibleForTooLong, initErrorStr, motionNoiseStr, opts.measurementNoise, opts.thresh.type, opts.cell.size);\[videosPath, inVideoname, ∼\] = fileparts(pathInputVideo);videoNameOutputTrackRGB = sprintf('%s_track_rgb.avi', inVideoname);videoNameOutputTrackProc = sprintf('%s_track_proc.avi', inVideoname);videoNameOutputTrackBW = sprintf('%s_track_bw.avi', inVideoname);videoNameOutputBW = sprintf('%s_bw.avi', inVideoname);tracksDir = fullfile(videosPath, 'tracks_kalmann_sel');tracksDirVideo = fullfile(tracksDir, inVideoname, paramsDir);opts.framesOrigDir = fullfile(tracksDir, inVideoname, 'frames');opts.framesProcDir = fullfile(tracksDirVideo, 'frameProc');opts.maskDir = fullfile(tracksDirVideo, 'frameMasks');opts.maskDirTracks = fullfile(tracksDirVideo, 'frameMasksTracks');opts.framesOrigTracksDir = fullfile(tracksDirVideo, 'framesOrigTracks');opts.framesProcTracksDir = fullfile(tracksDirVideo, 'framesProcTracks');opts.maskDirTracksAll = fullfile(tracksDirVideo, 'frameMasksTracksAll');opts.framesOrigTracksDirAll = fullfile(tracksDirVideo, 'framesOrigTracksAll');createVideoDirs(tracksDirVideo, opts); %\# creating output directoriesvideoObjTrackRGB = VideoWriter(fullfile(tracksDirVideo, videoNameOutputTrackRGB), 'Uncompressed AVI');videoObjTrackProc = VideoWriter(fullfile(tracksDirVideo, videoNameOutputTrackProc), 'Uncompressed AVI');videoObjTrackBW = VideoWriter(fullfile(tracksDirVideo, videoNameOutputTrackBW), 'Uncompressed AVI');videoObjBW = VideoWriter(fullfile(tracksDirVideo, videoNameOutputBW), 'Uncompressed AVI');fprintf('video: %s\\n',(fullfile(tracksDirVideo, videoNameOutputTrackRGB)));tracksObj = fullfile(tracksDirVideo, sprintf('%s.mat', inVideoname));obj = setupSystemObjects(pathInputVideo, opts);tracks = initializeTracks(); %\# Create an empty array of tracks.tracksHist = initializeTracksHistory();nextId = 1; % ID of the next tracknoFrames = 0;if ∼exist(tracksObj, 'file')%\# Detect moving objects, and track them across video frames.while ∼isDone(obj.reader)noFrames = noFrames + 1;fprintf('\# Processing frame: %d\\n', noFrames);frame = readFrame(obj);%\# image pre-processing and per-frame cell detection.\[centroids, bboxes, mask, frameDen\] = detectObjects(frame, opts);%\# predict cell location.\[tracks, tracksHist\] = predictNewLocationsOfTracks(tracks, tracksHist, noFrames);%\# link cells over time.\[assignments, unassignedTracks, unassignedDetections\] = ...detectionToTrackAssignment(tracks, centroids, bboxes, opts);%\# update existing cell-tracks.\[tracks, tracksHist\] = updateAssignedTracks(tracks, tracksHist, assignments, centroids, bboxes, noFrames);\[tracks, tracksHist\] = updateUnassignedTracks(tracks, tracksHist, unassignedTracks);%\# delete short tracks.\[tracks, tracksHist\] = deleteLostTracks(tracks, tracksHist, opts);%\# create new tracks.\[tracks, tracksHist, nextId\] = createNewTracks(tracks, tracksHist, centroids, bboxes, unassignedDetections, nextId, noFrames);%\# saving tracks to disk.dumpTrackingResults(frame, mask, tracks, tracksHist, tracksDirVideo, videoObjTrackRGB, videoObjTrackBW, videoObjBW, noFrames, opts);endopts.totNoFrames = noFrames;tracksHist = updateEmptyTracks(tracksHist, opts); %\# check empty tracks frames and reduce its totalVisibleCountsave(tracksObj, 'tracksHist', '-v7.3′); %\# save to disk the detected tracks.elsefprintf('\# Loading tracks\\n');tracksHist = load(tracksObj);tracksHist = tracksHist.tracksHist;reset(obj.reader);while ∼isDone(obj.reader)frame = readFrame(obj);noFrames = noFrames + 1;endfprintf('\# No of. frames: %d\\n', noFrames);endopts.totNoFrames = noFrames;if ∼isfield(tracksHist, 'numEmptyMask')tracksHist = updateEmptyTracks(tracksHist, opts);endopen(videoObjTrackRGB); %\# create RGB video with cell tracks.open(videoObjTrackProc); %\# create RGB video for cell tracks (segmented/cells + bounding boxes).open(videoObjTrackBW); %\# create BW video for cell tracks (segmented/detected cells + bounding boxes).open(videoObjBW);%\# create BW video file for cell detections (segmented/detected cells as binarys masks).noFrames = 0;for ff = 1:opts.totNoFramesnoFrames = noFrames + 1;frameOrigFile = fullfile(opts.framesOrigDir, sprintf('frame\_%05d.tif', ff));frameDenFile = fullfile(opts.framesProcDir, sprintf('frame\_%05d.tif', ff));frameMaskFile = fullfile(opts.maskDir, sprintf('frame\_%05d.tif', ff));fprintf('\#Processing frame: %d\\n', noFrames);if exist(frameOrigFile, 'file') && exist(frameDenFile, 'file') && exist(frameMaskFile, 'file')frameOrig = imread(frameOrigFile);frameDen = imread(frameDenFile);frameMask = imread(frameMaskFile);%\# storing into disk each frame overlayed with the cell-tracks.saveTrackingResults(frameOrig, frameDen, frameMask, tracksHist, videoObjTrackRGB, videoObjTrackProc, videoObjTrackBW, videoObjBW, ff, opts);endendclose(videoObjTrackRGB); %\# closing videoFile.close(videoObjTrackProc); %\# closing videoFile.close(videoObjTrackBW); %\# closing videoFile.close(videoObjBW); %\# closing videoFile.endfunction tracksThresh2Activations(videoName)% tracksThresh2Activations: given the extracted cell-tracks of a% given video (linked cells over time), this function detects which of% the cells got activated. For that purposes, the mean pixel intensity% of a segmented cell is computed at each frame. If the mean pixel% intensity value is higher than a threshold, then an activation is fired.% The original intensity values can also be smoothed to remove noise and if% the interval of the activation is too short, then a false-positive activation% is detected.%% Input:%   videoName, e.g., videoName = 'hu_NE1uM_2.avi';%% Output:%   a set of figures are stored into disk, containing a%   matrix-representation of the activated cell-signals.addpath(genpath('./3rd/overlay/'));%\# reading default parameters, e.g., location of detected cells frames.opts = getDefaultParameters();if ∼isfield(opts, 'endThreatment')opts.endThreatment = 10;endif ∼isfield(opts, 'signal')opts.signal = \[\];endif ∼isfield(opts.signal, 'Type')opts.signal.Type = 'orig';end%\# smoothing type for the cell signal.if ∼isfield(opts.signal, 'smoothType')opts.signal.smoothType = 'box'; % 'golay', 'gauss', 'box'end%\# threshold valueif ∼isfield(opts.signal, 'threshVal')opts.signal.threshVal = 1.25;end%\# minimum duration of cell-activationif ∼isfield(opts.signal, 'pruneEventDuration')opts.signal.pruneEventDuration = 5;endif ∼isfield(opts.signal, 'fillGaps')opts.signal.fillGaps = true;endif ∼isfield(opts.signal, 'fillGapsSze')opts.signal.fillGapsSze = 5;end\[videosPath, videoNameInput, ∼\] = fileparts(videoName);digitStr = '%d-';strAllMotionDigits = repmat(digitStr, 1, numel(opts.motionNoise));motionNoiseStr = sprintf(strAllMotionDigits(1:end-1),opts.motionNoise);strAllInitErrorDigits = repmat(digitStr, 1, numel(opts.initialEstimateError));initErrorStr = sprintf(strAllInitErrorDigits(1:end-1),opts.initialEstimateError);paramsDir = sprintf('%s_LRate%2.2f_visi%2.2f_age%d_invib%d_initErr%s_motNoise%s_measNoise%d\_%s_cSze%d', ...opts.motionModel, opts.learningRate, opts.trackVisibility, opts.ageThreshold, ...opts.invisibleForTooLong, initErrorStr, motionNoiseStr, opts.measurementNoise, opts.thresh.type, opts.cell.size);%\# creating subdirectories where resuls are going to be stored.tracksDir = fullfile(videosPath, 'tracks_paper');tracksDirVideo = fullfile(tracksDir, videoNameInput, paramsDir);signalDir = fullfile(tracksDirVideo, 'signal');signalThreshDir = fullfile(signalDir, 'thresh');signalEventsDir = fullfile(signalDir, 'events');if ∼exist(signalEventsDir, 'dir'), mkdir(signalEventsDir); endtracksFile = fullfile(tracksDirVideo, 'validTracksIdx.mat');validTracksIdx = load(tracksFile);validTracksIdx = validTracksIdx.validTracksIdx;%\# loading detected cell-tracksif strcmpi(opts.signal.Type, 'orig')threshSubDir = fullfile(signalThreshDir, 'origdata');signalMeanFile = fullfile(tracksDirVideo, 'signalMean.mat');signalMean = load(signalMeanFile);signalMean = signalMean.signalMean;signalMean(∼validTracksIdx,:) = \[\];signalArray = signalMean;if ∼exist(threshSubDir, 'dir'), error('Unknown directory: %s\\n', threshSubDir); endsignalEventsDir = fullfile(signalEventsDir, 'origdata');if ∼exist(signalEventsDir, 'dir'), mkdir(signalEventsDir); endsignalTypeStr = opts.signal.Type;tracksIdx = find(validTracksIdx);elseif strcmpi(opts.signal.Type, 'smooth')fprintf('\# Loading %s data\\n', opts.signal.smoothType);signalSmoothFile = fullfile(signalDir, 'smooth', sprintf('tracksSummary\_%s.mat', opts.signal.smoothType));signalMeanSmooth = load(signalSmoothFile);signalMeanSmooth = signalMeanSmooth.signalMeanSmooth;signalMeanSmooth(∼validTracksIdx,:) = \[\];signalArray = signalMeanSmooth;threshSubDir = fullfile(signalThreshDir, opts.signal.smoothType);if ∼exist(threshSubDir, 'dir'), error('Unknown directory: %s\\n', threshSubDir); endsignalEventsDir = fullfile(signalEventsDir, opts.signal.smoothType);if ∼exist(signalEventsDir, 'dir'), mkdir(signalEventsDir); endsignalTypeStr = sprintf('%s-%s', opts.signal.Type, opts.signal.smoothType);tracksIdx = 1:size(signalArray,1);elseerror('Unkown type: %s', opts.signal.Type);endsignalArrayNormFilename = fullfile(threshSubDir, 'signalNorm.mat');if ∼exist(signalArrayNormFilename, 'file'), error('Unknown file: %s\\n', signalArrayNormFilename); endsignalNorm = load(signalArrayNormFilename);signalNorm = signalNorm.signalNorm;%\# thresholding for activation.signalBinaryActivation = signalNorm \> opts.signal.threshVal;\[noTracks, ∼\] = size(signalBinaryActivation);%\# fill possible gaps in the cell-activationsif opts.signal.fillGaps \> 0filledSignal = signalBinaryActivation;for ii = 1:noTracksfilledSignal(ii,:) = ∼bwareaopen(∼filledSignal(ii,:), opts.signal.fillGapsSze);endsignalBinaryActivation = filledSignal;strFillGap = sprintf('fillSze%d', opts.signal.fillGapsSze);elsestrFillGap = sprintf('nofill');endsignalActivation = zeros(size(signalBinaryActivation));if opts.signal.pruneEventDuration \> 0strPruneEvent = sprintf('pruned%d', opts.signal.pruneEventDuration);elsestrPruneEvent = sprintf('noprune');end%\# analyzing cell-track duration.stats = repmat(struct('startIdx',\[\], 'endIdx', \[\], 'duration', \[\], 'eventIdx', \[\], 'activation', 0), noTracks, 1);for tt = 1:noTrackstrackActivation = signalBinaryActivation(tt,:);trackActivation = diff(\[0 trackActivation 0\]);eventStartIdx = find(trackActivation \> 0);eventEndIdx = find(trackActivation \< 0)-1;eventDuration = eventEndIdx - eventStartIdx + 1;if opts.signal.pruneEventDurationstringIdx = (eventDuration \> = opts.signal.pruneEventDuration);eventStartIdx = eventStartIdx(stringIdx);eventEndIdx = eventEndIdx(stringIdx);endeventIdx = zeros(1,max(eventEndIdx)+1);eventIdx(eventStartIdx) = 1;eventIdx(eventEndIdx+1) = eventIdx(eventEndIdx+1)-1;eventIdx = find(cumsum(eventIdx));signalActivation(tt, eventIdx) = 2;signalActivation(tt,eventStartIdx) = +1;signalActivation(tt,eventEndIdx) = −1;stats(tt).startIdx = eventStartIdx;stats(tt).endIdx = eventEndIdx;stats(tt).duration = eventDuration;stats(tt).eventIdx = eventIdx;stats(tt).activation = isempty(eventIdx) = = 0;endvideoName4Plot = strrep(videoNameInput,'\_','\\\_');signalImFilename = fullfile(signalEventsDir, sprintf('%s_signal\_%s_label.tif', videoNameInput, signalTypeStr));normSignalFilename = fullfile(signalEventsDir, sprintf('%s_signal_norm.tif', videoNameInput));activationSignalFilename = fullfile(signalEventsDir, sprintf('%s_signal_activ\_%s\_%s\_%s.tif', videoNameInput, strPruneEvent, strFillGap, signalTypeStr));binActivationSignalFilename = fullfile(signalEventsDir, sprintf('%s_signal_bin_activ\_%s\_%s\_%s.tif', videoNameInput, strPruneEvent, strFillGap, signalTypeStr));signalEventsDirBox = strrep(signalEventsDir, 'origdata', 'box');activationBoxSignalFilename = fullfile(signalEventsDirBox, sprintf('%s_signal_activ\_%s\_%s\_%s.mat', videoNameInput, signalTypeStr, strPruneEvent, strFillGap));activationBoxSignalFilename = strrep(activationBoxSignalFilename, 'orig', 'smooth-box');signalActivationBox = load(activationBoxSignalFilename);signalActivationBox = signalActivationBox.signalActivation;signal2disk(signalArray, videoName4Plot, signalImFilename, opts);signal2disk(signalNorm, videoName4Plot, normSignalFilename, opts);signal2disk(signalActivation, videoName4Plot, activationSignalFilename, opts);signal2disk(signalActivation∼ = 0, videoName4Plot, binActivationSignalFilename, opts);overlaySignalFilename = fullfile(signalEventsDir, sprintf('%s_signal_overlay\_%s\_%s\_%s.tif', videoNameInput, strPruneEvent, strFillGap, signalTypeStr));overlayNormSignalFilename = fullfile(signalEventsDir, sprintf('%s_signal_overlaynorm\_%s\_%s\_%s.tif', videoNameInput, strPruneEvent, strFillGap, signalTypeStr));signal2diskOverlay(signalArray, signalActivation∼ = 0, videoName4Plot, overlaySignalFilename, opts);signal2diskOverlay(signalNorm, signalActivation∼ = 0, videoName4Plot, overlayNormSignalFilename, opts);overlaySignalFilename = fullfile(signalEventsDir, sprintf('%s_signal_overlay\_%s\_%s\_%s_box.tif', videoNameInput, strPruneEvent, strFillGap, signalTypeStr));overlayNormSignalFilename = fullfile(signalEventsDir, sprintf('%s_signal_overlaynorm\_%s\_%s\_%s_box.tif', videoNameInput, strPruneEvent, strFillGap, signalTypeStr));signal2diskOverlay(signalArray, signalActivationBox∼ = 0, videoName4Plot, overlaySignalFilename, opts);signal2diskOverlay(signalNorm, signalActivationBox∼ = 0, videoName4Plot, overlayNormSignalFilename, opts);signalFilenameMat = fullfile(signalEventsDir, sprintf('%s_signal_activ\_%s\_%s\_%s.mat', videoNameInput, signalTypeStr, strPruneEvent, strFillGap));save(signalFilenameMat, 'signalActivation');signalStatsFilenameMat = fullfile(signalEventsDir, sprintf('%s_stats\_%s\_%s\_%s.mat', videoNameInput, signalTypeStr, strPruneEvent, strFillGap));save(signalStatsFilenameMat, 'stats');end
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